tiprankstipranks
Trending News
More News >

Cartesian announces first participant enrolled in Phase 3 AURORA trial

Cartesian Therapeutics (RNAC) announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis. Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy product candidate targeting B-cell maturation antigen. Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors. The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living score of three points or more at Month 4 compared to placebo.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue